| Description | RGH 1756 is an atypical antipsychotic with high affinity to dopamine D(3) receptors that leads to c-Fos induction in a unique pattern. |
| Synonyms | RGH-1756 |
| molecular weight | 462.61 |
| Molecular formula | C26H30N4O2S |
| CAS | 207277-37-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Gémesi LI, Kapás M, Szeberényi S. Application of LC-MS analysis to the characterisation of the in vitro and in vivo metabolite profiles of RGH-1756 in the rat. J Pharm Biomed Anal. 2001 Mar;24(5-6):877-85. PubMed PMID: 11248481. 2. Kovács KJ, Csejtei M, Laszlovszky I. Double activity imaging reveals distinct cellular targets of haloperidol, clozapine and dopamine D(3) receptor selective RGH-1756. Neuropharmacology. 2001 Mar;40(3):383-93. PubMed PMID: 11166331. 3. Sóvágó J, Farde L, Halldin C, Schukin E, Schou M, Laszlovszky I, Kiss B, Gulyás B. Lack of effect of reserpine-induced dopamine depletion on the binding of the dopamine-D3 selective radioligand, [11C]RGH-1756. Brain Res Bull. 2005 Oct 15;67(3):219-24. PubMed PMID: 16144658. 4. Terjéki E, Kapás M. An HPLC/UV method for the determination of RGH-1756 in dog and rat plasma. J Pharm Biomed Anal. 2001 Mar;24(5-6):913-20. PubMed PMID: 11248484. |